Kao Corporation 4452.JP
Kao has top-decile brands (Curel, Biore, Molton Brown) but bottom-decile management with a 'growth allergy' — fixing it Beiersdorf-style unlocks 76-97% upside.
Thesis
Kao Corporation, Japan's largest FMCG company, owns world-class derma-cosmetics brands like Curel, Biore, freeplus, Molton Brown and SENSAI, yet its shares have fallen 22.9% since 2021 while peers L'Oreal, Beiersdorf, Rohto and P&G gained 28-100%. Oasis argues management under President Yoshihiro Hasebe suffers a 'growth allergy': Curel is sold in just 12 countries while Cetaphil reaches 70+, marketing spend sits at 10.5% of revenue versus 20-35% at peers, the SKU count has doubled while consumer-goods sales grew only 1.7% CAGR, and the K27 medium-term plan even eliminated the group sales target. The board has no international consumer-marketing expertise. Drawing on Beiersdorf's 2021 turnaround under new CEO Vincent Warnery, Oasis demands a four-pillar fix — commit to global expansion, refine the brand portfolio, hire a leading CMO, and strengthen board oversight — claiming 76% SOTP and 85-97% DCF upside.
SCQA
Kao is Japan's largest FMCG company at ¥2.66tn market cap, owning a portfolio of world-class derma-cosmetics, mass skincare, haircare and household brands including Curel, Biore, freeplus, Molton Brown, SENSAI and Kate Tokyo.
Despite top-decile brands, Kao shares fell 22.9% since 2021 while peers gained 28-100%, ROE collapsed below 5%, Curel sells in only 12 countries, and the K27 plan reveals a 'growth allergy' under President Hasebe.
Commit to global expansion of cosmetics brands, refine the bloated portfolio, hire an external CMO and embrace digital marketing, and reinforce the board with international consumer-marketing expertise — emulating Beiersdorf's 2021 turnaround under Vincent Warnery.
Sum-of-parts valuation implies 76% upside; DCF implies 85-97% upside — equity value of ¥9,919 per share versus the ¥5,676 current price, with re-rating in line with global FMCG peers.
The three reasons
- 1
Kao owns top-decile brands (Curel, Biore, Molton Brown, SENSAI) but management has a 'growth allergy'
- 2
Curel sells in 12 countries vs. Cetaphil 70+; marketing spend 10.5% of revenue vs. peers 20-35%
- 3
Beiersdorf's 2021 CEO-led turnaround is the playbook; 76% SOTP / 85-97% DCF upside available
Primary demands
- Commit to global expansion of cosmetics and skincare brands beyond Japan/Asia
- Refine the bloated brand portfolio: concentrate on G11 brands, premiumize, rationalize SKUs
- Hire a leading external CMO and embrace digital marketing, content and influencer channels
- Strengthen oversight: appoint outside directors with international consumer-marketing expertise; improve board diversity and transparency
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Beiersdorf turnaround under CEO Vincent Warnery (2021)
- Fujitec (Oasis 2022 campaign)
- Tokyo Dome (Oasis 2019 campaign)
- P&G brand rationalization (post-2018, +111.8% shareholder return)
- Unilever premiumization and reorganization
- L'Oreal CeraVe (39% revenue growth in 2023)
Notable slides (6)
Notes
Public campaign launched with dedicated microsite (abetterkao.com) and full 'a better kao' brand system — unusually polished for an activist deck and clearly designed for direct-to-shareholder/consumer reach. Cover has no presentation date; date inferred (April 2024) from latest cited analyst reports (CLSA Feb 20, 2024) and Q1 2024 share-return data. Stake size not disclosed in this document. Memorable rhetorical devices: 'top decile brands, bottom decile management', 'growth allergy', 'flat-earth' joke around Kao's 'Global Sharp Top' slogan, AI-generated 'Refresh' mockups for Curel/Kate/Molton Brown/Oribe contrasted with 'Current' state. Beiersdorf-as-precedent (Vincent Warnery 2021 turnaround) is the central analogue. Oasis cites its own prior Japan campaigns (Fujitec, Tokyo Dome) as track record. Heavy use of management quote-contradictions (Hasebe on marketing fees vs Kao's underperformance; 'we have too many businesses' admission).